The company leverages the expertise of experts in therapeutics from Oxford University, the Hebrew University, and Stanford University to develop groundbreaking clinical programs that address areas of inflammation for which there are no effective therapies. Their primary platform is a novel anti-TNF program to treat fibrosis.